OUD & MAR: Caring for Our College Communities Speaker: - - PowerPoint PPT Presentation

oud mar
SMART_READER_LITE
LIVE PREVIEW

OUD & MAR: Caring for Our College Communities Speaker: - - PowerPoint PPT Presentation

OUD & MAR: Caring for Our College Communities Speaker: Elisabeth Fowlie Mock, MD, MPH Video Resources Diversion Alert/recoveryinme video https://www.youtube.com/watch?v=q1lSmWWwM40 CDC Videos RX Awareness Campaign Trailer (1:53)


slide-1
SLIDE 1

OUD & MAR:

Caring for Our College Communities

slide-2
SLIDE 2
slide-3
SLIDE 3

Speaker: Elisabeth Fowlie Mock, MD, MPH

slide-4
SLIDE 4

Video Resources

† Diversion Alert/recoveryinme video

https://www.youtube.com/watch?v=q1lSmWWwM40

† CDC Videos

RX Awareness Campaign Trailer (1:53) & Brenda’s Rx Awareness Story (0:30)

“How can I be addicted to these? I get them from my doctor. It kills your soul and makes you feel worthless.” https://www.cdc.gov/rxawareness/resources/video.html

† Leighton MAT trailer https://www.youtube.com/watch?v=WjtYp_pMUqI

slide-5
SLIDE 5

Disclosures

† MICIS does not accept any money from

pharmaceutical companies

† This presentation includes “off label use” of

medications

slide-6
SLIDE 6

Objectives

At the conclusion of the MICIS learning session, the learner will have the ability to:

1. Appropriately recognize, diagnose and language opioid use disorder (OUD) 2. Compare pharmacologic treatments used in Medication Assisted Recovery (MAR) 3. Develop a strategy for treating acute pain for patients with OUD 4. Constantly consider harm reduction

slide-7
SLIDE 7

Materials May Include

† “un-ad” one page handout for each topic † How to Use Naloxone (pt brochure) † ME Law slides/Chapter 21 rules † DHHS prescription guide † National/state numbers † Evidence & Resource document at

MICISMAINE.org

slide-8
SLIDE 8

OUR COLLEGE COMMUNITIES

slide-9
SLIDE 9

Opioid Use Disorder is a Chronic Disease

typically, a chronic, relapsing, yet treatable illness; associated with significantly increased rates of morbidity and mortality

(Strain, 2018)

slide-10
SLIDE 10

Use in Adolescence

† 9 of 10 people with addiction started

smoking, drinking or using drugs before age 18

† The earlier the substance use, the greater the

likelihood of addiction

† Average age of first use 13-14 years

(Essentials of Addiction Medicine, 2015)

slide-11
SLIDE 11

High School Students— EtOH, Tobacco & Drugs

† 75% have used 1 or > substances † ~50% are current users † 12.5% meet diagnostic criteria for addiction

slide-12
SLIDE 12

YOUTH SUBSTANCE USE IS A HEALTH THREAT RATHER THAN A NORMAL RITE OF PASSAGE

slide-13
SLIDE 13

Reducing Risk

† Delay all substance use for as long as possible † Be vigilant for signs of risk † Intervene appropriately

slide-14
SLIDE 14

U.S. life expectancy declined for 2 years in a row (2014-2016), largely because of unintentional injuries (includes unintentional OD).

(NCHS Data Brief No. 293, 2016)

slide-15
SLIDE 15

15

slide-16
SLIDE 16

Maine Overdose Deaths

slide-17
SLIDE 17

Challenge Question

Name the four counties in Maine that had OD deaths higher than proportion to population size (from Attorney General OD report, 2017 statistics)

slide-18
SLIDE 18

2017 Overdose Deaths by County

25 18 109 82 <10 47 11 65 18 13 <10 <10 <10 <10 <10 Deaths proportional to population size Deaths higher than proportion to population size

2017 Drug Deaths Report – ME Attny Genl’s Office Slide courtesy of Lisa Letourneau/ME Quality Counts

slide-19
SLIDE 19

Opioid-related ED Visits July 2016 – Sept 2017

† Increase of 34% in Maine † Massachusetts, New Hampshire, Rhode Island

had ‘nonsignificant’ decreases (<10%)

† Maine noted to be one of 16 states with high

prevalence of overdose mortality

(Vivolo-Kantor, 2018)

slide-20
SLIDE 20

There are several studies that demonstrate the negative impact of using demeaning, pejorative, or stigmatizing language — such language doesn’t just hurt feelings — the research shows that when such language is used people are less likely to get the medical care they so desperately need.

  • Omar Manejwala, MD, Addiction Specialist
slide-21
SLIDE 21

BEST PRACTICES

slide-22
SLIDE 22

We Need to Be Prepared to Recognize and Treat OUD

slide-23
SLIDE 23

Review/fill-in the diagnostic criteria for OUD

†Two †Larger †Desire †Time †Craving †Failure †Despite †Given up †Hazardous †Caused

slide-24
SLIDE 24

Recovery

v a process of change v improving health and wellness v living a self-directed life v striving to reach full potential v no “one size fits all” approach

(SAMSHA, 2012)

slide-25
SLIDE 25

10 Guiding Principles of Recovery

(SAMSHA, 2012)

slide-26
SLIDE 26

Four Dimensions that Support a Life in Recovery

Health Home Purpose Community

(SAMSHA website)

slide-27
SLIDE 27

OUD/MAR Myths Exercise

slide-28
SLIDE 28

MAR: Effective, Cost-effective, and Cost-beneficial

Medications:

† reduce illicit opioid use † retain people in treatment † reduce risk of opioid overdose death † better than treatment with placebo or no

medication

slide-29
SLIDE 29

Who Can Prescribe?

† Buprenorphine, † Methadone, † Emergency methadone or

buprenorphine (72h),

† Naltrexone

slide-30
SLIDE 30

Newer Buprenorphine Formulations

† subdermal implant (6 months) † injection (monthly)

slide-31
SLIDE 31

Naltrexone

† Initiation of naltrexone must be preceded by

withdrawal from opioids (preferably medically supervised);

† oral naltrexone has higher dropout rates than

injectable.

slide-32
SLIDE 32

Recovery Occurs via Many Pathways

† one year recovery rates:

– 50% with medication-assistance, – 10% without medication

(multiple sources cited in references)

slide-33
SLIDE 33

Which Patients Are Best Suited for tx in Primary Care Settings?

slide-34
SLIDE 34

Hub & Spokes Collaborate

Hubs Spokes

Patients Information Consultation Training High intensity MAT Methadone, buprenorphine, naltrexone Regional locations All staff specialize in addictions treatment Maintenance MAT Buprenorphine, naltrexone Community locations Lead provider + nurse and LADC/MA counselor

slide-35
SLIDE 35

National Buprenorphine Data

~50%

  • f those ever

prescribe 2% of all prescribers have an x-waiver ~50%

  • f those prescribe

1-4 patients (SAMSHA)

slide-36
SLIDE 36

Maine Buprenorphine Prescribers

Docs (30 limit) Docs (100 limit) Docs (275 limit) NPs (30 limit*) PAs (30 limit*)

Data: SAMSHA, January 2018, Abstracted by Lisa Letourneau, MD, MPH *all NP/PA are in first year of license with 30 pt limit

slide-37
SLIDE 37

How long to treat?

Indefinite. Some patients:

† may slowly taper and wean after 1-2 years of

stability

† remain on low dose therapy long-term † may go on and off treatment

slide-38
SLIDE 38

Bias may be a Barrier

Emergency physicians at Hopkins had lower regard for pts with SUDs than other medical conditions with behavioral components. at least “somewhat agree” that they prefer not to work pts with SUD who have pain

(Mendiola, 2018)

54

%

slide-39
SLIDE 39

Hardwire Harm Reduction Strategies in All Medical Practices

slide-40
SLIDE 40

SAVE LIVES FIRST

Harm Reduction

slide-41
SLIDE 41

Social Determinants of Health Contribute to the Opioid Epidemic

Homeless persons were 9x more likely to die from OD than persons stably housed. A “housing first” approach to recovery increases likelihood of success. (Baggett, 2013)

slide-42
SLIDE 42

Social Determinants of Health Contribute to the Opioid Epidemic

Persons who are released from incarceration are at a 12x risk of overdose. Most jails/prisons do not provide MAR.

slide-43
SLIDE 43

Harm Reduction

† Prescribe opioids using conservative

management strategies

† Limit supplies to 3-5 days for acute pain † Avoid co-prescribing with BZDP † Exhaust nonopioid and nonpharmacologic

treatment strategies (for acute or chronic)

† Document informed consent

slide-44
SLIDE 44

Consider Naloxone Prescriptions for:

† all patients on chronic

  • pioids, especially at doses
  • ver 50 MME

† any patient co-prescribed

benzodiazepines/sedatives

  • r actively using alcohol

† friends or family members

who might witness

  • verdose

† patients with OUD being

released from incarceration

  • r treatment programs

† patients with history of

  • verdose

† patients with underlying

respiratory disease, especially sleep apnea

† all patients in MAR

slide-45
SLIDE 45

Acute Pain in Patients with OUD

slide-46
SLIDE 46

Baseline opioid maintenance therapies are not adequate for pain control in patients with acute, moderate to severe injuries and surgeries beyond minor procedures.

slide-47
SLIDE 47

In Patients on Methadone and Buprenorphine:

† verify the dose † maximize nonopioid pain treatments (pharmacologic and nonpharmacologic) † consider increasing or splitting dose † add higher dose short-acting opioids for

3-5d

slide-48
SLIDE 48

Actively using heroin/other opioid:

† try to get a history of ‘dose’ † maximize non-opioid modalities † consider tramadol † always try to use oral medications in preference

  • ver IV

† consider increased doses post-operatively † avoid take-home prescriptions in most cases

slide-49
SLIDE 49

In Patients on Naltrexone:

† try to delay elective interventions † maximize nonopioid pain treatments (pharmacologic and nonpharmacologic) † if emergency may need higher than usual

doses of opioids to overcome—high risk of respiratory depression

slide-50
SLIDE 50

Contact recovery medication prescriber proactively or as soon as possible in unscheduled/emergent situations to discuss acute pain needs, taper schedule, and who will handle prescribing

slide-51
SLIDE 51

In Summary...

slide-52
SLIDE 52

Ø The words you use to describe OUD and an individual with OUD are powerful. Ø Recovery is possible and more likely when using medications combined with counselling Ø OUD medications reduce illicit opioid use, reduce

  • verdose deaths, decrease crime and retain

people in treatment/counselling Ø Treat acute pain with multiple modalities for all patients, including those in recovery Ø Recommend naloxone prescriptions for all patients in recovery

slide-53
SLIDE 53

MICISTravels on facebook references: MICISMaine.org

slide-54
SLIDE 54

The words you use to describe OUD and an individual with OUD are powerful. Providers should adopt terminology that will not reinforce prejudice, negative attitudes, or discrimination.

  • Omar Manejwala, MD, Addiction Specialist
slide-55
SLIDE 55

Counselors help clients by…

addressing the challenges & consequences of OUD

slide-56
SLIDE 56

Maine Overdose Deaths

50 100 150 200 250 300 350 400 450 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total Deaths Pharmaceutical Opioid Deaths Illicit Opioid Deaths

slide-57
SLIDE 57

Words are important. If you want to care for something, you call it a ‘flower’; if you want to kill something, you call it a ‘weed’.

  • Don Coyhis, Native American Recovery coach
slide-58
SLIDE 58

“Use of marijuana, stimulants, or other addictive drugs should not be a reason to suspend OUD tx. However, evidence demonstrates pts actively using substances during OUD tx have a poorer prognosis. The use of EtOH, bzdp and other sedative hypnotics may be a reason to suspend agonist tx—safety concerns related to respiratory depression.” (ASAM Guideline, 2015)